MedTrace Logo

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

NCT04291781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-09-19

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.

Conditions

Interventions

BIOLOGICAL

RC18 160mg

subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

BIOLOGICAL

RC18 240mg

subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

BIOLOGICAL

placebo

subcutaneous injection on the upper arm, abdomen, or upper thigh outside;

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong Zhang, M.D. · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-13
Primary Completion
2021-05-20
Completion
2021-05-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04291781 on ClinicalTrials.gov